HomeCompareHLBZF vs ABBV

HLBZF vs ABBV: Dividend Comparison 2026

HLBZF yields 1.77% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HLBZF wins by $38.37M in total portfolio value· pulled ahead in Year 4
10 years
HLBZF
HLBZF
● Live price
1.77%
Share price
$208.42
Annual div
$3.69
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.47M
Annual income
$34,705,923.06
Full HLBZF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HLBZF vs ABBV

📍 HLBZF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLBZFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLBZF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLBZF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLBZF
Annual income on $10K today (after 15% tax)
$150.61/yr
After 10yr DRIP, annual income (after tax)
$29,500,034.60/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HLBZF beats the other by $29,478,978.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLBZF + ABBV for your $10,000?

HLBZF: 50%ABBV: 50%
100% ABBV50/50100% HLBZF
Portfolio after 10yr
$19.29M
Annual income
$17,365,347.41/yr
Blended yield
90.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HLBZF
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
2.6
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLBZF buys
0
ABBV buys
0
No recent congressional trades found for HLBZF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLBZFABBV
Forward yield1.77%3.06%
Annual dividend / share$3.69$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$38.47M$102.3K
Annual income after 10y$34,705,923.06$24,771.77
Total dividends collected$38.15M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusSellBuy

Year-by-year: HLBZF vs ABBV ($10,000, DRIP)

YearHLBZF PortfolioHLBZF Income/yrABBV PortfolioABBV Income/yrGap
1$11,054$354.38$11,550$430.00$496.00ABBV
2$12,560$732.24$13,472$627.96$912.00ABBV
3$14,995$1,555.13$15,906$926.08$911.00ABBV
4← crossover$19,515$3,470.15$19,071$1,382.55+$444.00HLBZF
5$29,322$8,441.39$23,302$2,095.81+$6.0KHLBZF
6$55,082$23,707.96$29,150$3,237.93+$25.9KHLBZF
7$142,184$83,245.48$37,536$5,121.41+$104.6KHLBZF
8$553,783$401,645.91$50,079$8,338.38+$503.7KHLBZF
9$3,516,558$2,924,010.24$69,753$14,065.80+$3.45MHLBZF
10$38,468,640$34,705,923.06$102,337$24,771.77+$38.37MHLBZF

HLBZF vs ABBV: Complete Analysis 2026

HLBZFStock

HeidelbergCement AG, together with its subsidiaries, produces and distributes cement, aggregates, ready-mixed concrete, and asphalt worldwide. It provides cement products, natural stone aggregates, such as sand and gravel; crushed aggregates comprising stone chippings and crushed stones; and concrete/ready-mixed concrete for use in the construction of tunnels or bridges, office buildings, or schools, as well as to produce precast concrete parts consisting of stairs, ceiling elements, or structural components. In addition, it provides asphalt primarily used as a top layer in road construction, as well as trades in cement, clinker, secondary cementitious materials, and solid and alternative fuels. HeidelbergCement AG was founded in 1873 and is headquartered in Heidelberg, Germany.

Full HLBZF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HLBZF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLBZF vs SCHDHLBZF vs JEPIHLBZF vs OHLBZF vs KOHLBZF vs MAINHLBZF vs JNJHLBZF vs MRKHLBZF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.